Expand IGC Menu
IGC MENU

IGC Latest Press Releases

-- February 2, 2026 --

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation ACCESS Newswire 8:30 AM

-- January 22, 2026 --

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York ACCESS Newswire 9:00 AM

-- January 6, 2026 --

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability ACCESS Newswire 8:05 AM

-- January 5, 2026 --

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial ACCESS Newswire 9:00 AM

-- December 19, 2025 --

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum ACCESS Newswire 9:00 AM

-- December 15, 2025 --

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines ACCESS Newswire 9:00 AM

-- December 10, 2025 --

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." ACCESS Newswire 9:00 AM

-- December 9, 2025 --

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial ACCESS Newswire 9:00 AM

-- December 2, 2025 --

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease ACCESS Newswire 9:00 AM

-- November 25, 2025 --

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends ACCESS Newswire 9:00 AM

-- November 17, 2025 --

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital ACCESS Newswire 8:30 AM

-- November 13, 2025 --

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders ACCESS Newswire 9:00 AM

-- November 10, 2025 --

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025 ACCESS Newswire 9:00 AM

-- November 3, 2025 --

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline ACCESS Newswire 8:53 AM

-- October 22, 2025 --

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant" ACCESS Newswire 9:00 AM

-- October 14, 2025 --

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences ACCESS Newswire 9:00 AM

-- October 10, 2025 --

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders ACCESS Newswire 7:50 PM

-- October 7, 2025 --

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease ACCESS Newswire 9:00 AM

-- September 29, 2025 --

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial ACCESS Newswire 9:00 AM

-- September 24, 2025 --

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology ACCESS Newswire 9:00 AM

-- September 22, 2025 --

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial ACCESS Newswire 9:00 AM

-- September 9, 2025 --

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection ACCESS Newswire 9:17 AM
Market Data Delayed 15 Minutes